Free Trial
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free TRIB Stock Alerts

Trinity Biotech (TRIB) Competitors

Trinity Biotech logo
$0.60 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$0.60 +0.00 (+0.17%)
As of 05/22/2026 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TRIB vs. MTVA, GNPX, MTEX, CELZ, and BCLI

Should you buy Trinity Biotech stock or one of its competitors? MarketBeat compares Trinity Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Trinity Biotech include MetaVia (MTVA), Genprex (GNPX), Mannatech (MTEX), Creative Medical Technology (CELZ), and Brainstorm Cell Therapeutics (BCLI). These companies are all part of the "pharmaceutical products" industry.

How does Trinity Biotech compare to MetaVia?

MetaVia (NASDAQ:MTVA) and Trinity Biotech (NASDAQ:TRIB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

MetaVia currently has a consensus target price of $20.00, suggesting a potential upside of 419.48%. Given MetaVia's stronger consensus rating and higher probable upside, analysts clearly believe MetaVia is more favorable than Trinity Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MetaVia
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Trinity Biotech
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

1.4% of MetaVia shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 0.8% of MetaVia shares are held by company insiders. Comparatively, 8.2% of Trinity Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MetaVia has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat MetaVia's return on equity.

Company Net Margins Return on Equity Return on Assets
MetaViaN/A -172.92% -89.39%
Trinity Biotech -85.36%N/A -36.62%

In the previous week, MetaVia had 12 more articles in the media than Trinity Biotech. MarketBeat recorded 13 mentions for MetaVia and 1 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 0.00 beat MetaVia's score of -0.27 indicating that Trinity Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MetaVia
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Trinity Biotech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MetaVia has higher earnings, but lower revenue than Trinity Biotech. MetaVia is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MetaViaN/AN/A-$12.97M-$5.19N/A
Trinity Biotech$43.78M0.05-$37.38M-$3.90N/A

Summary

Trinity Biotech beats MetaVia on 8 of the 14 factors compared between the two stocks.

How does Trinity Biotech compare to Genprex?

Trinity Biotech (NASDAQ:TRIB) and Genprex (NASDAQ:GNPX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Genprex has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat Genprex's return on equity.

Company Net Margins Return on Equity Return on Assets
Trinity Biotech-85.36% N/A -36.62%
Genprex N/A -247.32%-176.73%

In the previous week, Trinity Biotech had 1 more articles in the media than Genprex. MarketBeat recorded 1 mentions for Trinity Biotech and 0 mentions for Genprex. Trinity Biotech's average media sentiment score of 0.00 equaled Genprex'saverage media sentiment score.

Company Overall Sentiment
Trinity Biotech Neutral
Genprex Neutral

79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by insiders. Comparatively, 0.3% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Genprex has lower revenue, but higher earnings than Trinity Biotech. Trinity Biotech is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trinity Biotech$43.78M0.05-$37.38M-$3.90N/A
GenprexN/AN/A-$16.23M-$14.14N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Genprex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Trinity Biotech beats Genprex on 8 of the 11 factors compared between the two stocks.

How does Trinity Biotech compare to Mannatech?

Trinity Biotech (NASDAQ:TRIB) and Mannatech (NASDAQ:MTEX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Mannatech has higher revenue and earnings than Trinity Biotech. Mannatech is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trinity Biotech$43.78M0.05-$37.38M-$3.90N/A
Mannatech$108.04M0.08-$15.21M-$6.71N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Mannatech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Mannatech has a net margin of -11.97% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat Mannatech's return on equity.

Company Net Margins Return on Equity Return on Assets
Trinity Biotech-85.36% N/A -36.62%
Mannatech -11.97%-2,383.34%-40.24%

In the previous week, Mannatech had 6 more articles in the media than Trinity Biotech. MarketBeat recorded 7 mentions for Mannatech and 1 mentions for Trinity Biotech. Mannatech's average media sentiment score of 0.85 beat Trinity Biotech's score of 0.00 indicating that Mannatech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Trinity Biotech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Mannatech
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by company insiders. Comparatively, 41.5% of Mannatech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Mannatech beats Trinity Biotech on 7 of the 13 factors compared between the two stocks.

How does Trinity Biotech compare to Creative Medical Technology?

Trinity Biotech (NASDAQ:TRIB) and Creative Medical Technology (NASDAQ:CELZ) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

In the previous week, Trinity Biotech had 1 more articles in the media than Creative Medical Technology. MarketBeat recorded 1 mentions for Trinity Biotech and 0 mentions for Creative Medical Technology. Trinity Biotech's average media sentiment score of 0.00 equaled Creative Medical Technology'saverage media sentiment score.

Company Overall Sentiment
Trinity Biotech Neutral
Creative Medical Technology Neutral

Creative Medical Technology has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company Net Margins Return on Equity Return on Assets
Trinity Biotech-85.36% N/A -36.62%
Creative Medical Technology N/A -88.38%-84.71%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Creative Medical Technology
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by company insiders. Comparatively, 1.7% of Creative Medical Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Creative Medical Technology has lower revenue, but higher earnings than Trinity Biotech. Creative Medical Technology is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trinity Biotech$43.78M0.05-$37.38M-$3.90N/A
Creative Medical Technology$10K884.30-$5.99M-$2.14N/A

Summary

Trinity Biotech beats Creative Medical Technology on 7 of the 11 factors compared between the two stocks.

How does Trinity Biotech compare to Brainstorm Cell Therapeutics?

Trinity Biotech (NASDAQ:TRIB) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%.

Company Net Margins Return on Equity Return on Assets
Trinity Biotech-85.36% N/A -36.62%
Brainstorm Cell Therapeutics N/A N/A -519.50%

79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Trinity Biotech. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trinity Biotech$43.78M0.05-$37.38M-$3.90N/A
Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$1.64N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Brainstorm Cell Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Brainstorm Cell Therapeutics had 1 more articles in the media than Trinity Biotech. MarketBeat recorded 2 mentions for Brainstorm Cell Therapeutics and 1 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 0.00 equaled Brainstorm Cell Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Trinity Biotech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Brainstorm Cell Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Brainstorm Cell Therapeutics beats Trinity Biotech on 6 of the 10 factors compared between the two stocks.

Get Trinity Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRIB vs. The Competition

Export
MetricTrinity BiotechMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market CapN/A$8.52B$6.46B$12.34B
Dividend YieldN/A2.50%2.76%5.28%
P/E Ratio-0.1516.2420.9925.66
Price / Sales0.058.28560.3086.31
Price / CashN/A17.1143.4956.67
Price / Book-0.034.0610.417.14
Net Income-$37.38M$224.05M$3.57B$335.98M
7 Day Performance6.53%5.34%6.41%4.15%
1 Month Performance-6.10%-0.08%3.55%2.54%
1 Year Performance-82.63%0.98%34.12%35.06%

Trinity Biotech Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRIB
Trinity Biotech
0.5668 of 5 stars		$0.60
flat		N/A-82.6%$0.00$43.78MN/A480
MTVA
MetaVia
1.8228 of 5 stars		$1.61
+44.6%		$20.00
+1,146.1%		-55.7%$8.34MN/AN/A8
GNPX
Genprex
0.2877 of 5 stars		$0.78
-3.5%		N/A-94.0%$8.23MN/AN/A20
MTEX
Mannatech
1.3611 of 5 stars		$4.21
+2.2%		N/A-55.6%$8.13M$108.04MN/A250
CELZ
Creative Medical Technology
0.708 of 5 stars		$2.22
-0.4%		N/A+18.3%$8.10M$10KN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TRIB) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel